Celltrion Healthcare recently presented research from two studies conducted on its CT-P13 subcutaneous (SC) formulation (biosimilar infliximab) demonstrating positive results for the use of CT-P13 SC in the treatment of active Crohn’s disease and rheumatoid arthritis.  According to Celltrion, the data from each study shows the efficacy and safety of the subcutaneous administration of CT-P13 SC is comparable to the CT-P13 intravenous (IV) formulation up to week 30 in patients with either Crohn’s disease or rheumatoid arthritis.

Mr. Hyoung-Ki Kim, Vice Chairman at Celltrion, stated Celltrion “plan[s] to launch CT-P13 SC next year if approved as part of [Celltrion’s] ‘twin-track’ strategy to create more choice and synergy across the healthcare system.”